(Q40008136)

English

Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

diabetic nephropathy

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

author name string

Li Li Guo

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Yu Pan

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Hui Min Jin

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

0 references

publication date

22 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1876-1883

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Adiponectin is inversely associated with renal function in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Serum adiponectin and renal dysfunction in men with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Elevated levels of high-molecular-weight adiponectin in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Adiponectin acts in the brain to decrease body weight.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN770

21 January 2018

Identifiers

10.1093/NDT/GFN770

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40008136&oldid=1882331452"